A股異動 | 斯萊克(300382.SZ)直線拉昇漲超10% 與螞蟻區塊鏈簽署服務協議
格隆匯9月30日丨斯萊克(300382.SZ)午後直線拉昇,現報9.68元,漲10.88%,暫成交1.8億元,最新總市值54億元。斯萊克今日午間發公告稱,公司當日與螞蟻區塊鏈簽署了《螞蟻區塊鏈溯源平台服務協議》。協議約定螞蟻區塊鏈作為斯萊克螞蟻鏈保真鏈體系運營合作項目的承包方,為斯萊克提供全產業鏈及合作所需的SaaS服務,包括螞蟻商流鏈服務平台和溯源管理服務、支付寶掃碼服務等支撐服務事宜。雙方就區塊鏈在商品防偽溯源方面展開深入合作。公告稱,本次合作將有助於公司未來成為區塊鏈實體標籤設備製造商,對提高公司核心競爭力、未來業績的提升等具有積極影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.